Entrada's Duchenne Drug Met Safety Goals, But Dystrophin Rose Just 0.10% At The Lowest Dose

Cohort 2 at a doubled 10 mg/kg dose is fully enrolled, with data targeted for the first half of 2027.

Share
Entrada's Duchenne Drug Met Safety Goals, But Dystrophin Rose Just 0.10% At The Lowest Dose

Dystrophin, the muscle protein Duchenne patients lack, rose a mean 0.10% from baseline in six Entrada Therapeutics trial participants given ENTR-601-45 at 5 mg/kg, against a 0.02% mean decrease on placebo, according to an 8-K filed Wednesday. The company called the first cohort's results positive because the drug met its safety and tolerability goals, while no functional benefit was expected or seen at this dose.

What the Cohort 1 data show

The study, ELEVATE-45-201, is a placebo-controlled trial of ENTR-601-45 in ambulatory patients aged four to 20 whose Duchenne is amenable to exon 45 skipping. Cohort 1 enrolled eight participants, randomized 3:1 to the drug or placebo, with doses on days one, 43 and 85.

The dystrophin gain carried a nominal p-value of 0.03. Exon skipping, a measure of whether the drug is working on the gene's reading frame, rose a mean 0.15% in five treated participants, with no p-value calculated, versus a 0.04% mean decrease on placebo.

The company's own notes say the lower limit of quantification for dystrophin was 0.25%. Two treated participants had baseline levels below that line.

On function, the company said that, given participants' age and baseline function, no observable benefit was expected or observed after three doses. Function will be assessed with higher doses and longer dosing.

On safety, headache was the most common adverse event, with 5 events in 2 participants. One participant had 2 serious events, vomiting and pyrexia (fever), which resolved. No one discontinued, all participants moved into the open-label extension, and kidney and magnesium markers stayed in normal ranges.

What it changes

The case for the drug now rests on higher doses. Cohort 2 enrollment is complete and dosing at 10 mg/kg is ongoing. Cohort 3, at up to 15 mg/kg, follows.

Entrada said plasma exposures matched predictions from juvenile non-human primate data, and that modeled exposures give it confidence in a significant dystrophin increase in the later cohorts. That is the company's expectation, not a result.

Natarajan Sethuraman, Entrada's President of Research and Development, pointed to the dosing schedule: once every six weeks, or "approximately nine administrations per year instead of more than fifty" for families on a weekly infusion regimen. He also cited an Independent Data Monitoring Committee recommendation to proceed to 18 mg/kg in Cohort 3 of the sister ELEVATE-44-201 study.

If you hold the stock, TRDA closed at $4.86 on Tuesday, down 11.64% for that session, before the data came out Wednesday morning.

Cohort 2 data at 10 mg/kg are due in the first half of 2027, the first test of whether a higher dose delivers the significant dystrophin increase management expects.

Sources